Laskin Carl A, Clark Christine A, Spitzer Karen A
Division of Rheumatology, Department of Medicine, University of Toronto Faculty of Medicine, Toronto, ON M5G 2K4, Canada.
Rheum Dis Clin North Am. 2005 May;31(2):255-72, vi. doi: 10.1016/j.rdc.2005.01.011.
This article compares the manifestations of systemic lupus erythematosus (SLE) in the presence and absence of antiphospholipid antibodies (aPLs), the hallmark autoantibodies of antiphospholipid syndrome (APS). The combination of SLE and APS appears to be of greater concern than either entity alone. APS complicates SLE by adding a vaso-occlusive factor to the inflammatory component that adversely affects the prognosis of those who have lupus and aPLs. The increase in both morbidity and mortality when both are present has significant therapeutic implications. Anticoagulation may be a safer and more appropriate therapeutic option than instituting a regimen of corticosteroids and immunosuppressive agents with all their attendant adverse effects. It falls upon the physician to clearly define the disease entity and fully evaluate the disease process.
本文比较了抗磷脂抗体（aPLs）存在和不存在时系统性红斑狼疮（SLE）的表现，抗磷脂抗体是抗磷脂综合征（APS）的标志性自身抗体。SLE与APS的合并似乎比单独的任何一种疾病更令人担忧。APS通过在炎症成分中增加血管闭塞因素使SLE复杂化，这对患有狼疮和aPLs的患者的预后产生不利影响。两者同时存在时发病率和死亡率的增加具有重要的治疗意义。与采用具有所有伴随不良反应的皮质类固醇和免疫抑制剂方案相比，抗凝可能是一种更安全、更合适的治疗选择。明确界定疾病实体并全面评估疾病过程是医生的责任。
